Adding Bavarian Nordic (BVNRY) $10.50 Adding to Watch CoronaVirus List.

Wait Until Robinhood Traders Find Out About This!


Actually it’s not a cure, it’s just a vaccine – but don’t let rumor-traders know! They don’t bother to check details – as in ready – don’t bother aiming – fire.

It is nonetheless huge news, as they’d probably make more money from a vaccine, than they would from a cure…as this could prevent 33 million serious respiratory infections a year,

Even though you’ve probably never heard of it, Bavarian Nordic is not a startup or small-cap. They recently received an order from the US government valued at $202 million. They’re working on stuff for Small-pox, Monkey-pox, Ebola, and even good-old Herpes. Currently valued at just $1.9 billion – nothing compared to Corona market cap leaders like Moderna at $26 billion.

The first news of significance related to CoronaVirus popped up on May 6th (see below) when it was trading around $7.00 – so in our opinion, we are not too late to the game. Like 3rd inning, maybe.

As reported in the Journal of Infectious Diseases. In plain English, also below.


LIVE QUOTE

Quote on London Stock Exchange $202.

LIVE CHART


PIPELINE


A Vaccine Against a Widespread Common Cold Type Just Passed Promising Clinical Trials (Science Alert – 8/12/2020)

A vaccine designed to prevent one of the most widespread common cold types has just delivered promising results in the latest set of clinical trials, and the developers now think it could actually reach the market in just a few years. 

The cold, known as respiratory syncytial virus (RSV), is so common, more than 90 percent of kids contract it by the age of two. In fact, this dangerous and sometimes deadly infection is the leading cause of serious lower respiratory diseases in children worldwide, and we still don’t have a working vaccine to prevent it.

While Bavarian Nordic, the German company that owns this particular vaccine – known as MVA-BN-RSV – hopes it will become available in 2024, the medicine still has to pass a third clinical trial before the US Food and Drug Administration (FDA) would approve it for general use.

So far, it appears as though a single dose of this new vaccine safely induces a broad immune response to RSV in most of the 420 adults over the age of 55 that were enrolled in the study.

Not only is RSV good at hiding from the immune system, its presence does not induce long-lasting immunity, like chicken pox or measles might, which means we can keep on getting sick with the same thing over and over again, even as adults.

A vaccine could potentially stop 33 million serious respiratory infections a year, saving the lives of nearly 60,000 children annually. That would be a huge deal, and while there’s reason to be hopeful, it’s important not to get ahead of ourselves. There are many almost-vaccines out there, on the brink of hitting the market in the next five years.

The third clinical trial is set to start in 2021 and will include more than 12,000 adults. Hopefully that will be enough to answer some of these remaining questions.

A vaccine could potentially stop 33 million serious respiratory infections a year, saving the lives of nearly 60,000 children annually. That would be a huge deal, and while there’s reason to be hopeful, it’s important not to get ahead of ourselves. There are many almost-vaccines out there, on the brink of hitting the market in the next five years.

Read full article here.


First Quarter Conference Call Transcript


OTHER CORONA RELATED NEWS

July 22nd: Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine

Last month, encouraging preclinical data for the vaccine candidate were reported, demonstrating the induction of very high levels of neutralizing antibodies against SARS-CoV-2, compared to published preclinical data from other COVID-19 vaccines in development.

May 6th: Bavarian Nordic Enters Agreement with AdaptVac to Advance COVID-19 Vaccine Program

Bavarian Nordic A/S today announced that it has entered into an exclusive head of terms agreement with AdaptVac, a joint venture established by ExpreS2ion Biotechnologies and NextGen Vaccines spun out of the University of Copenhagen, to license AdaptVac’s proprietary capsid virus like particle (VLP) based SARS-CoV-2 subunit vaccine.

Kinda Related: Relief and Worry as Bavarian Brewery Reopens to Guests.


ANALYST COVERAGE

NEWS ARCHIVE

Offices in Denmark, Germany and the Research Triangle in Morrisville, North Carolina

Not a client.


THE HAND SANITIZER YOU’VE ALWAYS DREAMED OF..

99.9% EFFECTIVE, NON-TOXIC, NON-FLAMMABLE AND NON-ALCOHOL.